Challenges on the Road to Recovery: Exploring Attitudes and Experiences of Clients in a Community-based Buprenorphine Program in Baltimore City

Overview

Journal Addict Behav

Specialties Psychiatry
Social Sciences

Date 2019 Jan 26

PMID 30682677

Citations 9

Authors

C Truong

N Krawczyk

M Dejman

S Marshall-Shah

K Tormohlen

D Agus

J Bass

Affiliations

Soon will be listed here.

Abstract

Objective: This qualitative study identifies and describes experiences and challenges to retention of individuals with opioid use disorder (OUD) who participated in a low-threshold combined buprenorphine-peer support treatment program in Baltimore.

Methods: In-depth semi-structured interviews with staff and former clients of the Project Connections Buprenorphine Program (PCBP) (9 people) and focus group discussions with current and previous clients of PCBP (7 people) were conducted. Content analysis was used to extract themes regarding barriers to enrolling and remaining in, and transitioning from the program.

Results: Primary challenges identified by the participants included struggles with cravings and symptoms of withdrawal, comorbid mental health issues, criminal justice system involvement, medication stigma, and conflicts over level of flexibility regarding program requirements and the role of employment.

Conclusions: This study identified several obstacles clients face when seeking care through a combined buprenorphine-peer support model. Findings highlight potential programmatic factors that can be improved and additional resources that may support treatment retention rates and better outcomes. Despite challenges, low-threshold and community-based programs can increase access to effective maintenance treatment for OUD, especially among vulnerable populations who may not have access to formal health services.

Citing Articles

Barriers and facilitators to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals during community reentry.

Chladek J, Chui M Explor Res Clin Soc Pharm. 2025; 17:100561.

PMID: 39896177 PMC: 11786854. DOI: 10.1016/j.rcsop.2025.100561.

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review.

Chladek J, Chui M Front Public Health. 2024; 12:1377193.

PMID: 38803812 PMC: 11128549. DOI: 10.3389/fpubh.2024.1377193.

Patient and Provider Perspectives on Processes of Engagement in Outpatient Treatment for Opioid Use Disorder: A Scoping Review.

Austin E, OBrien Q, Ruiz M, Ratzliff A, Williams E, Koch U Community Ment Health J. 2023; 60(2):330-339.

PMID: 37668745 DOI: 10.1007/s10597-023-01175-1.

Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder.

Clifton J, Belcher A, Greenblatt A, Welsh C, Cole T, Davis A J Psychedelic Stud. 2023; 6(2):80-87.

PMID: 36686617 PMC: 9850635. DOI: 10.1556/2054.2022.00214.

Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.

Krawczyk N, Maniates H, Hulsey E, Smith J, DiDomenico E, Stuart E J Addict Med. 2022; 16(6):645-652.

PMID: 35165225 PMC: 9653109. DOI: 10.1097/ADM.0000000000000981.

References

Krawczyk N, Feder K, Fingerhood M, Saloner B . Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug Alcohol Depend. 2017; 178:512-518. PMC: 5557040. DOI: 10.1016/j.drugalcdep.2017.06.009. View

Everly J, DeFulio A, Koffarnus M, Leoutsakos J, Donlin W, Aklin W . Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction. 2011; 106(7):1309-18. PMC: 3107896. DOI: 10.1111/j.1360-0443.2011.03400.x. View

McNiel D, Binder R, Robinson J . Incarceration associated with homelessness, mental disorder, and co-occurring substance abuse. Psychiatr Serv. 2005; 56(7):840-6. DOI: 10.1176/appi.ps.56.7.840. View

Simon C, Tsui J, Merrill J, Adwell A, Tamru E, Klein J . Linking patients with buprenorphine treatment in primary care: Predictors of engagement. Drug Alcohol Depend. 2017; 181:58-62. DOI: 10.1016/j.drugalcdep.2017.09.017. View

Daniels A, Salisbury-Afshar E, Hoffberg A, Agus D, Fingerhood M . A novel community-based buprenorphine program: client description and initial outcomes. J Addict Med. 2014; 8(1):40-6. DOI: 10.1097/ADM.0000000000000004. View

Binswanger I, Stern M, Deyo R, Heagerty P, Cheadle A, Elmore J . Release from prison--a high risk of death for former inmates. N Engl J Med. 2007; 356(2):157-65. PMC: 2836121. DOI: 10.1056/NEJMsa064115. View

Florence C, Zhou C, Luo F, Xu L . The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016; 54(10):901-6. PMC: 5975355. DOI: 10.1097/MLR.0000000000000625. View

Barnett P, Rodgers J, Bloch D . A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001; 96(5):683-90. DOI: 10.1046/j.1360-0443.2001.9656834.x. View

Viron M, Zioto K, Schweitzer J, Levine G . Behavioral Health Homes: an opportunity to address healthcare inequities in people with serious mental illness. Asian J Psychiatr. 2014; 10:10-6. DOI: 10.1016/j.ajp.2014.03.009. View

10.

Nolan S, Hayashi K, Milloy M, Kerr T, Dong H, Dias Lima V . The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015; 156:57-61. PMC: 4633383. DOI: 10.1016/j.drugalcdep.2015.08.037. View

11.

Kourounis G, David Wensley Richards B, Kyprianou E, Symeonidou E, Malliori M, Samartzis L . Opioid substitution therapy: Lowering the treatment thresholds. Drug Alcohol Depend. 2016; 161:1-8. DOI: 10.1016/j.drugalcdep.2015.12.021. View

12.

Rolfe G . Validity, trustworthiness and rigour: quality and the idea of qualitative research. J Adv Nurs. 2006; 53(3):304-10. DOI: 10.1111/j.1365-2648.2006.03727.x. View

13.

Northrup T, Stotts A, Green C, Potter J, Marino E, Walker R . Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Addict Behav. 2014; 41:20-8. PMC: 4252696. DOI: 10.1016/j.addbeh.2014.09.021. View

14.

Krawczyk N, Picher C, Feder K, Saloner B . Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. Health Aff (Millwood). 2017; 36(12):2046-2053. PMC: 6035729. DOI: 10.1377/hlthaff.2017.0890. View

15.

Deering D, Sheridan J, Sellman J, Adamson S, Pooley S, Robertson R . Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav. 2011; 36(6):636-642. DOI: 10.1016/j.addbeh.2011.01.004. View

16.

Hager B, Hasselberg M, Arzubi E, Betlinski J, Duncan M, Richman J . Leveraging Behavioral Health Expertise: Practices and Potential of the Project ECHO Approach to Virtually Integrating Care in Underserved Areas. Psychiatr Serv. 2018; 69(4):366-369. DOI: 10.1176/appi.ps.201700211. View

17.

Metzger D, Woody G, McLellan A, OBrien C, Druley P, Navaline H . Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr (1988). 1993; 6(9):1049-56. View

18.

Zemore S . The effect of social desirability on reported motivation, substance use severity, and treatment attendance. J Subst Abuse Treat. 2011; 42(4):400-12. PMC: 3296824. DOI: 10.1016/j.jsat.2011.09.013. View

19.

Connery H . Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015; 23(2):63-75. DOI: 10.1097/HRP.0000000000000075. View

20.

Brewer D, Catalano R, Haggerty K, Gainey R, Fleming C . A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998; 93(1):73-92. View